Who are the leading producers of stem cells in 2014 and what are their prospects? This new study explains

Tuesday 6 May 2014, Amsterdam

A new report, available on ASDReports, forecasts the world market for stem cell technologies will reach $12.2bn in 2018, with strong growth to 2024. That forecast and others appear in Pharma Leader Series: Top Stem Cell Technology Companies 2014-2024, published in March 2014. That analysis predicts the future of the overall stem cells market and prospects for leading companies in the US, Europe, Israel and Asia.

This new investigation predicts the overall market for stem cell technologies will expand from 2014 to 2024, benefiting patients, healthcare providers and biomedical companies. In 2012 cancer therapy represented the largest therapeutic application of stem cell treatments, accounting for 45.4% of the total market. Companies also show interest in stem cells for non-therapeutic applications, such as screening in drug development. That application lowers R&D costs and hastens development of drugs. Thus the analysts believes more pharma companies will use that developmental approach from 2014, stimulating revenue generation in that segment for stem cells.

Hemant Mistry, a pharmaceutical industry analyst, said: “In early 2014 there are few stem cell-based therapies available on the market. However interest has grown significantly owing to their potential in providing “miracle cures” for diseases. This potential gives opportunity for stem cell-based treatments to reach multiple end markets.

“The biggest challenge stem cell companies face is attracting investment from venture capital firms, or through alliances with big pharmaceutical companies. A clinical trial for a cell-based treatment is expensive and requires substantial financial backing. Without that support, companies may have to terminate late-stage R&D programmes or cease to operate. The investment and support of a large pharmaceutical company also increases the reach and distribution of those cellular products after market launch, in a sales partnership.”

That new report analyses 22 leading stem cell companies in the US, Europe, Israel and Asia. It explores products, financial results and trends in research and development (R&D pipelines), also forecasting revenues to 2024 at company level.

The contents of company profiles differ, but that study covers details such as these:

• Technologies, R&D pipelines, products and financial performance
• Acquisitions, alliances, technological applications and clinical developments
• Strengths, weaknesses, opportunities and threats to business (SWOT forces)
• Revenues to 2024 (stem cell forecasts for 18 companies).

This study also forecasts revenues to 2024 for the overall world stem cells industry and five submarkets:

• Cancer treatment (oncology)
• Cardiovascular (CV) applications
• Central nervous system (CNS) uses
• Other therapy using those biological agents
• Non-therapeutic cellular products.

Pharma Leader Series: Top Stem Cell Technology Companies 2014-2024 evaluates leading companies developing stem cell products.